Single-nucleotide polymorphisms (SNPs) can be assayed using DNA isolated from archival formalin-fixed, paraffin-embedded (FFPE) samples, making retrospective pharmacogenetic studies possible. In this study, we describe methods that significantly increase the number of SNP determinations possible using FFPE samples. Quantifying the amount of DNA amenable to PCR (amplification-quality DNA, AQ-DNA) allows a significant reduction in the amount of sample required for Taqman-based SNP assays. Optimizing AQ-DNA input increases PCR amplification efficiency and SNP determination accuracy. DNA was extracted from 39 FFPE tumor sections and matched tumor and stromal cores, which were of the type used to generate tissue microarrays. Sections and tumor cores yielded sufficient AQ-DNA for more than 1000 SNP determinations. Seven SNPs were assessed following individual assay optimization for minimal AQ-DNA. Genotypes from tumor cores for single SNPs were 92.3-100% concordant with those obtained from sections. Using these methods, the number of SNP genotypes that can be determined from single FFPE samples is greatly increased expanding the genetic association studies possible from limited archival specimens. The use of tumor cores is of particular importance as the harvesting of tumor cores has minimal impact on the utility of the donor blocks for other purposes.
Introduction
Until recently, clinical trials in cancer did not routinely collect and store patient DNA samples, thus limiting the ability to conduct pharmacogenetic analysis of many large, landmark clinical trials. Another potential source of patient DNA does, however, exist in the form of formalin-fixed, paraffin-embedded (FFPE) tumor samples that were collected for the majority of clinical trials in oncology. Previously, we and others have demonstrated that DNA can be obtained from these tumor blocks, that single-nucleotide polymorphism (SNP) genotypes can be reliably determined from this DNA, and that the genotypes of SNPs in genes of pharmacogenetic interest (primarily involved in drug metabolism) derived from the tumor samples match those of the germline DNA. [1] [2] [3] [4] This technological advance demonstrated that FFPE samples could be used for pharmacogenetic analyses of historical prospective clinical trials, thereby allowing the existing wealth of large, carefully conducted clinical trials of chemotherapeutic agents to be mined for associations between inherited gene variants with drug toxicities and clinical outcomes.
Using the DNA extracted from FFPE tumor samples for genotype analyses presents significant technical challenges due to the relatively low quantity and poor quality of the template DNA that is extracted from these samples. Standard DNA isolation methods used for FFPE samples typically produce severely sheared and fragmented DNA, which is frequently not optimal for PCR-based genotyping. [5] [6] [7] [8] All commonly used PCR-based genotyping assays have been designed to work using high-quality DNA isolated from viable cells. Real-time PCR-based Taqman assays, for instance, involve the amplification of DNA segments 80-150 base pairs (bp) in length containing the SNP of interest. 9 In addition, 5-10 mm FFPE tissue block sections typically only yield sufficient DNA for 30-50 Taqman-based genotyping reactions (MJS and JNT, unpublished observations). Furthermore, Taqman PCR reactions using DNA extracted from FFPE samples are frequently inefficient, and yield irregular fluorescence output curves, making allelic determination difficult or ambiguous. Common practice when confronted with DNA samples that are difficult to genotype is to increase the amount of template DNA used per reaction. However, we have observed that doing this with FFPE-derived DNA often results in worsening rather than improvement of the PCR reaction. A simple method to determine the optimal amount of a given sample of FFPE-derived DNA for each assay would be valuable.
In this report, we describe methods to analyze DNA harvested from FFPE materials that allows the assessment of overall quality and quantification of 'amplification-quality DNA' or 'AQ-DNA' (DNA fragments large enough for efficient PCR-based analysis). Using materials evaluated in this manner, we describe how minimizing the amount of input DNA in Taqman-based genotyping reactions significantly improves PCR amplification efficiency, increases the accuracy of allelic determinations, and greatly increases the number of genotyping assays that can be performed per sample. We also demonstrate that the FFPE tumor cores of the type used to generate tissue microarrays (TMAs) can be used as a source of DNA for Taqman-based genotyping. The methodological approaches described herein facilitate the improved application of Taqman-based SNP genotyping to FFPE-derived DNA, significantly increasing the number of assays that can be conducted using what is a valuable and limited tissue resource.
Materials and methods

Sample preparation
Samples were selected randomly from the routinely formalin-fixed, paraffin-processed breast tumor archive at the Royal Marsden Hospital, with the prerequisites that they (i) were pre-2006 in order to comply with the Human Tissue Act legislation with regard to patient consent, and (ii) were suitable to TMA core acquisition from both the tumor and intratumoral stromal compartments. In practice, these were predominantly invasive ductal carcinomas grade II/III. At the time of DNA extraction, tumor blocks ranged in age from 4 to 19 years, with a median age of 15 years. Specific FFPE samples used in each data figure are indicated in Supplementary Table S1 .
Tumor and stromal areas were marked on a hematoxylin and eosin-stained slide and then transposed onto the associated paraffin block. Cores (0.6 mm) were punched in the marked areas using the Beecher tissue arrayer MTA1 (Beecher Instruments, Sun Prairie, WI, USA) and the extracted cores were transferred to RNAse-and Dnase-free tubes. The needle punch was cleaned with ethanol and allowed to dry fully between each core acquisition to prevent cross contamination. Two 10 mm paraffin-embedded sections were cut from the same paraffin block before core acquisition. A new blade was used for each patient sample to eliminate the potential for cross-contamination. Gloves were worn at all times.
DNA extraction from FFPE tissue samples Our previously described method for extracting DNA from FFPE samples 2 using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA) was improved with minor modification to eliminate the use of solvents to de-paraffin samples. Briefly, samples (sections and cores, described above) were heated to 95 1C for 15 min in 180 ml Buffer ATL and then allowed to cool to room temperature for a minimum of 5 min. 20 ml of proteinase K solution (20 mg ml À1 ) was added to the samples, which were then incubated at 55 1C. After 8 h, fresh proteinase K solution (20 ml) was added and the samples were incubated for an additional 8 h, and then DNA was extracted according to the manufacturer's instructions.
Quality control multiplex PCR DNA quality was measured using a multiplex PCR-based method described by van Beers et al., 10 with minor modifications. In addition to primer pairs for the 100, 200, 300 and 400 bp fragments of GAPDH used by van Beers et al., additional primer pairs were added for 500, 600 and 700 bp fragments. Primer sequences are available on request. The 100 and 500-700 bp primers were used at a final concentration of 266 nM, and the 200-400 bp primers at 133 nM. Reactions were incubated at 94 1C for 1 min, 56 1C for 1 min and at 72 1C for 3 min, for 35 cycles. PCR products were analyzed by capillary electrophoresis using an Agilent 2100 Bioanalyzer with DNA 1000 electrophoresis chips (Agilent Technologies, Santa Clara, CA, USA).
Quantification of AQ-DNA
To determine the amount of AQ-DNA in extracted FFPE samples, we quantified the 100 bp fragment of GAPDH using SYBR Green real-time PCR. Briefly, 25 ml reactions containing forward (5 0 -GTTCCAATATGATTCCACCC-3 0 ) and reverse primers (5 0 -CTCCTGGAAGATGGTGATGG-3 0 ) at final concentrations of 250 nM, 12.5 ml of Platinum SYBR Green Master Mix (Invitrogen, Carlsbad, CA, USA) and template DNA were incubated for 40 cycles at 95 1C for 15 s and at 56 1C for 45 s using an iCycler real-time thermocycler (BioRad, Madison, WI, USA).
DNA was isolated from fresh human lymphocytes (Blood and Tissue Kit, Qiagen) and the concentration was measured using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). SYBR Green real-time PCR (described above) was performed using a dilution series of lymphocyte DNA (in Ultra-Pure H 2 O, Invitrogen) from 1 pg to 1 mg to generate standard curves. These standard curves were used to calculate the relative amount of AQ-DNA in FFPE-derived samples, compared with the high-quality lymphocyte DNA. Standard curves were plotted as the cycle number at which SYBR Green fluorescence passed a software-determined threshold (threshold cycle, Ct) vs DNA quantity (mg) using GraphPad Prism 4.03 (GraphPad Software, La Jolla, CA, USA). AQ-DNA from FFPE samples was quantified by adding 1 ml of each DNA sample per real-time PCR reaction. The threshold cycle for each FFPE sample was plotted on the standard curve to extrapolate the quantity of AQ-DNA, relative to the high-quality lymphocyte DNA.
DNA enzymatic shearing DNA was sheared enzymatically using an Enzyme Shearing Kit (Active Motif, Carlsbad, CA, USA). Genomic DNA from lymphocytes at B100 ng ml À1 was diluted at 1:10 with digestion buffer and 50 ml aliquots were made. Enzyme cocktail (2.5 ml) (1:10 000 in 50% glycerol) was added to each aliquot, and incubated for times ranging from 10 to 180 min. The reactions were stopped by adding 1 ml of ice-cold 0.5 M EDTA and by incubating on ice for 15 min. DNA was purified from shearing reactions for subsequent PCR using Nucleotide Clean-up kits (Qiagen) according to the manufacturer's instructions.
Genotyping FFPE tissue-extracted DNA was genotyped for known SNPs in the cytochrome P450 2D6 (CYP2D6) gene. The following SNPs were genotyped: 1846G4A (rs3892097), T1707del (rs5030655), A2549del (rs35742686), 2988G4A (rs28371725), 100C4T (rs1065852) and 4180G4C (rs1135840). Genotyping for these SNPs allows the identification of the most common variant alleles of CYP2D6: CYP2D6*2, *3, *4, *6, *10 and *41. SNPs were determined using Taqman allelic discrimination assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions as previously described, 11 with minor modification. Reactions were carried out to 60 cycles to allow amplification of subnanogram quantities of DNA. Reactions were conducted using Genotyping Master Mix (Applied Biosystems) in an iCycler real-time thermocycler (BioRad). Samples were also genotyped for UGT2B7 802T4C (rs7439366) using a Taqman alleic discrimination assay with minor modification. Reactions were conducted, using 50 pg of DNA as determined by our methods described above, for 50 cycles on an iCycler real-time cycler.
To minimize the potential for DNA cross-contamination (a concern when amplifying subnanogram quantities of DNA), all genotyping reactions were prepared in a designated template-free zone in a vertical laminar flow hood (AirClean 600, AirClean Systems, Raleigh, NC, USA), with high-efficiency particulate air filtration and ultraviolet (UV) light.
Results
Multiplex PCR identifies samples of insufficient quality to genotype
To assess the quality of DNA from FFPE tissue samples, we adapted a method described by van Beers et al. in which seven amplicons of increasing size, from 100 to 700 bp, within the GAPDH gene are amplified by PCR. 10 The sizes of the amplicons produced using FFPE-derived template DNA correlates with the degree to which the DNA has been sheared or fragmented. We used this assay to screen a panel of DNA samples isolated from FFPE tissue. We selected samples that had previously been genotyped for a panel of SNPs in the cytochrome P450 2D6 (CYP2D6) gene successfully (thus considered higher quality, HQ DNA) and unsuccessfully (thus considered lower quality, LQ DNA). All seven fragments are amplified from the high-quality DNA control (lane 1). Samples that could not be genotyped (LQ) did not support amplification of any of the GAPDH fragments (shown in LQ samples, lanes 2-5). We observed that FFPE DNA samples that performed well using Taqman genotyping assays (HQ) supported amplification of at least the 100 bp fragment, and larger fragments up to 400 bp ( Figure 1 , lanes 6-9).
Quantification of AQ-DNA by real-time PCR Standard methods for quantifying DNA, such as UV absorbance, do not provide information with regard to the degree of DNA fragmentation; therefore, we set out to measure the amount of AQ-DNA in DNA samples from FFPE tissues. We developed a quantitative PCR-based assay that determines the amount of fragments of 100 bp or greater relative to a high molecular weight DNA standard harvested from viable lymphocytes. This technique uses SYBR Greenbased amplification and quantification of the 100 bp fragment of GAPDH from the quality control PCR described above. To validate that amplification of this fragment has a linear relationship with DNA quantity, a dilution series of high-quality DNA obtained from lymphocytes was generated as described in the Materials and methods.
The linear range of threshold cycle vs quantity of DNA was found to be 1 pg-10 ng (Figure 2a ). Interestingly, adding 410 ng of DNA to the PCR reaction caused a loss in the linear relationship, and caused inefficiency in PCR amplification ( Figure 2b) . Furthermore, addition of 1 mg of DNA completely quenched the PCR reaction and blocked any amplification (indicated by a threshold cycle of 39 cycles). The dashed line in Figure 2b represents the linear regression from Figure 2a , to demonstrate the loss of linearity at 410 ng of input DNA.
Sample quality by multiplex PCR correlates with quantification of AQ-DNA To demonstrate that quantification of the 100 bp fragment of GAPDH correlates with sample fragmentation as measured by the multiplex PCR described above, lymphocyte DNA was enzymatically sheared as described in the Materials and methods. The Enzymatic Shearing Kit was specifically designed so that increasing incubation time results in progressive fragmentation of the DNA. The overall quality and quantity of AQ-DNA was evaluated as described above.
As shown in Figure 3 , increased digestion time caused a progressive loss of the larger PCR amplicons, with loss of the 500-700 bp amplicons by 60 min, and loss of the 400 bp amplicon by 120 min. Overdigestion with high-concentration enzyme cocktail caused a loss of all bands (data not shown). Increased digestion time also correlated with a loss of AQ-DNA as determined by amplification of the 100 bp GAPDH fragment, with a progressive decrease in quantity of AQ-DNA from 0 to 120 min of digestion. AQ-DNA decreased from 17.5 ng ml À1 in the control digestion to B2 ng ml À1 at 4120 min digestion. Further digestion up to 180 min with this dilution of enzyme cocktail appeared to have no further effect on fragment size or 100 bp fragment quantification. Overdigestion with high-concentration enzyme cocktail caused no 100 bp amplicon signal to be seen with those samples, and decreased AQ-DNA to B0 ng ml À1 (data not shown).
Minimizing input DNA improves genotyping efficiency
On the basis of our quantification method described above, we attempted to establish the minimum amount of AQ-DNA required for assessment of genotypes using Taqman-based analyses. Ten FFPE-derived DNA samples were diluted from 1 ng to 10 pg of AQ-DNA per reaction, and genotyped for CYP2D6 1846G4A (CYP2D6*4). Results are shown in Table 1 . Samples with wild-type genotypes for this SNP were successfully genotyped with only 10 pg of input DNA. However, the mutant-specific probe in this assay required at least 50 pg of input DNA to amplify successfully. Importantly, sample J was genotyped as a homozygous mutant with 50 pg of input AQ-DNA, but a heterozygote with 100 pg or more of AQ-DNA. Thus, the minimum quantity of AQ-DNA required for genotyping the CYP2D6*4 allele was set at 100 pg. Additional optimization was performed using other Taqman assays. The UGT2B7 T848C (UGT2B7*2) assay required only 50 pg of AQ-DNA to reliably genotype samples. Other assays, including CYP2D6 A2549del (CYP2D6*3), required 150 pg or more of AQ-DNA to generate reliable genotype data (data not shown). Importantly, optimizing Taqman reactions by minimizing the amount of input AQ-DNA improved Taqman reaction efficiency, and allowed for less ambiguous genotype determinations ( Figure 4 ). To determine patient genotype, end point fluorescence from the Taqman-based PCR for each allele-specific probe is assigned to an axis on a scatter plot. A positive or negative signal from each probe is used to assign patient genotypes. However, the fluorescence output curves generated in real-time PCR are representative of efficient vs inefficient amplification, and can be used to evaluate potential false positives and negatives. Figure 4c , many of these genotypes are likely unreliable because of the lack of separation between samples deemed positive and negative for the wild-type allele (VIC fluorophore, y axis).
Tumor block cores yield equivalent amounts of AQ-DNA vs sections We next set out to determine whether tissue from tumor cores of the type generated for TMA construction, or cores from adjacent stromal tissue, could be used in pharmacogenomic analyses. To compare DNA yield from FFPE tumor block sections and core punches, we obtained 39 matched sets of sections, tumor cores and cores of adjacent stromal tissue (described in the Materials and methods). Samples were processed and AQ-DNA was quantified as described above. As shown in Figure 5a , sections yielded 1.25 ± 1.05 ng ml À1 of AQ-DNA, and tumor cores yielded 1.20 ± 0.91 ng ml À1 of AQ-DNA, indicating no significant difference in AQ-DNA yield between tumor sections and cores (P ¼ 0.19). These yields provide enough DNA for an average of B1250 and B1200 genotyping reactions, respectively, based on 100 ml of eluent per sample and 100 pg AQ-DNA per reaction. However, stromal cores yielded only 0.39 ± 0.52 ng ml À1 of AQ-DNA (B390 reactions on average), significantly less than both tumor cores and sections. Increased yield obtained from tumor sections correlated with increased yield from tumor cores (Figure 5b ). Yield from neither sections nor tumor cores correlated with yield obtained from stroma cores (data not shown). Abbreviations: AQ-DNA, amplification-quality DNA; het., heterozygote; WT, wild type; mut., mutant.
Maximizing SNP analyses from FFPE tumor samples MJ Sikora et al FFPE tumor block age has minimal impact on AQ-DNA yield At the time of DNA extraction, 12 of 39 sample sets (30.8%) were from FFPE tumor blocks o10 years old; the remaining 27 (69.2%) were X10 years old. We compared tumor block age to AQ-DNA yield for each sample type ( Figure 6 ). For sections, there was a slight, but statistically significant (P ¼ 0.0025) decrease in AQ-DNA yield with increasing block age (Figure 6a ; slope ¼ À0.1 ng ml À1 per year). The highest AQ-DNA yields from sections were obtained from blocks 4-6 years old. However, sections from blocks 14-19 years old routinely yielded AQ-DNA equivalent to blocks 6-13 years old. AQ-DNA yield from tumor cores (Figure 6b ) and stroma cores (Figure 6c ) had slight trends toward decreased yield with block age, but neither of these trends were statistically significant (P40.05).
Tumor DNA from sections or cores is higher quality than stroma core DNA Six matched samples from each type were chosen at random to assess overall sample type quality by multiplex PCR as described above. On average, DNA from tumor block sections was of greater quality than that from tumor cores or stroma cores ( Table 2 ). The maximum amplicon size obtained by multiplex PCR from each sample is shown in Table 2 . Section-derived DNA had a maximum amplicon size of 400 bp across all six samples, and an average maximum amplicon of 250 bp. Tumor and stroma core-derived DNA both had maximum amplicons of 300 bp, with average maximum amplicons of 200 and 150 bp, respectively. Further, although all six sets of section and tumor corederived DNA produced amplicons of at least 100 bp, three of the six stroma core-derived DNA samples produced no amplicons. Examples of multiplex PCR results for each sample type are shown for samples B and F in Supplementary Figure S1 . In both samples, section DNA produces the greatest amplicon size, though tumor and stroma cores do not amplify the larger amplicons.
To assess the ability to determine SNP genotypes using DNA from each tumor block sample type, the matched sample sets were genotyped for the UGT2B7*2 allele (802T4C). Samples were quantified as described above before genotyping, and reactions were optimized at 50 pg AQ-DNA per reaction (data not shown). Figures 7a-c show initial real-time fluorescence outputs for the wild-type probe of the UGT2B7 802T4C Taqman assay, for sections, tumor cores and stroma cores, respectively. In all, 38 of 39 tumor section samples were successfully genotyped, with only 1 inefficient PCR amplification curve that requires regenotyping (97.4% call rate). Altogether, 35 of 39 tumor core samples were successfully genotyped (89.7% success rate). The end point fluorescence difference between samples above and below threshold fluorescence was decreased in tumor core-derived DNA vs section-derived DNA, and four amplification curves ended near the calculated threshold. This difference was decreased further in the stroma corederived DNA, resulting in successful genotypes for only 30 out of 39 samples (76.9% call rate). Samples that could not be assigned a genotype after this initial run were reoptimized and reassessed. that genotypes from sections are 100% concordant with genotypes obtained from germline DNA. 2 We assessed the agreement between genotypes (concordance) for the CYP2D6 gene (requiring identification of 6 SNP genotypes, listed in the Materials and methods) and the UGT2B7*2 allele (data not shown). In all, 32 of 39 (82.1%) tumor core samples yielded identical CYP2D6 genotypes to section samples. However, five of seven discordant genotypes were likely the results of poor AQ-DNA yields (o0.1 ng ml À1 ) that were identified before genotype assessment. The two remaining samples differed in only a single SNP genotype (4180G4C; rs1135840). Only 27 of 39 stroma cores yielded identical CYP2D6 genotypes to the section samples, but half of the discordant samples (6 of 12) could be identified by low sample yield before genotyping. In total, 3 of 12 differed in only a single SNP genotype. There was a higher degree of concordance between sections and the other sample types for the single SNP UGT2B7*2 allele. In all, 36 of 39 (92.3%) tumor core genotypes or stroma core genotypes matched those obtained from section DNA, and 33 of 39 (84.6%) samples had matching genotypes from all 3 sample types. The three tumor core samples that had discordant results vs their matched section for the UGT2B7*2 allele had the lowest AQ-DNA yields of all tumor cores (o0.05 ng ml
À1
). 
Discussion
Archival FFPE tumor tissue is an invaluable potential source of DNA for retrospective pharmacogenetic analyses from large clinical trials, and a number of groups have begun to use this approach for studies in breast cancer, 3,12,13 colon cancer 1, 14 and leukemia. 4 Further, since our initial report, 2 advances in genotyping using Taqman-based assays and mass spectrometry 15 have been reported, and recently, highquality genomic copy number analysis using DNA from FFPE tissue 16 has been described. Despite the increasing use of FFPE samples for genotype analysis and improved methods, several key issues still significantly inhibit the wider application of this approach. The blocks from historical trials with long follow-up are a finite and valuable resource and, quite appropriately, access to these materials is tightly controlled. It is very important, therefore, that sample preparation and assay methods be rigorously optimized to maximize the amount of information that can be obtained from the minimum amount of tissue. Access to sections of blocks from important clinical trials is being further complicated by the increasing application of TMA technology. Immunohistochemistry-based methods can be applied very efficiently to TMA sections providing high-quality data with regard to the presence of tumor antigens within all the cases of entire clinical trials with a minimum expenditure of reagents and tumor tissues. As a result, there is an increasing trend toward the preparation of TMAs from the blocks from clinical trials, with the result that access to entire sections of each block is even more limited.
In this study, we therefore set out to achieve two goals: (1) to develop an approach to maximizing the genotyping assay yield that can be achieved from a given amount of DNA prepared from FFPE materials, and (2) to evaluate the practicality and utility of isolating DNA suitable for genotyping studies from cores of the type used to prepare TMAs. Our hope was that, by demonstrating the tremendous potential value of DNA harvested from TMA cores, we would encourage investigators contemplating the production of TMAs to harvest additional tumor cores at the time of TMA manufacture for the preparation of DNA for future genetic analysis.
DNA isolated from FFPE tissues is notoriously challenging to work with because of degradation, shearing and chemical modification, which can cause significant difficulty with downstream applications. [5] [6] [7] [8] This includes PCR-restriction fragment length polymorphism or Taqman-based assays, as both assays require minimum fragment lengths to be amplified efficiently for analysis. 2, 5, [17] [18] [19] Simple UV absorbance-based assessment of DNA quality and quantity does not adequately predict performance in PCR-based applications. 20 This is likely the result of small DNA fragments that inflate UV absorbance readings, in spite of being too small for efficient PCR. Ideally, genotyping reactions should be set up with just sufficient sample to provide enough DNA template of adequate fragment length to allow efficient amplification. This would minimize the amount of sample used and ensure optimal efficiency of the genotyping assay, thereby maximizing the number of genotyping reactions that can be conducted with a given sample. In this report, we describe the strategy we have used to optimize genotyping assays by (1) determining the amount of 'amplification quality DNA' or 'AQ-DNA' in FFPE-derived samples relative to a high-quality DNA calibrator, and (2) establishing the optimum amount of AQ-DNA required for individual assays. Previous reports have proposed or described various strategies for assessing the quality of DNA extracted from FFPE materials for subsequent assay. 10, [20] [21] [22] [23] In fact, a similar approach of quantifying amplifiable DNA was used successfully by Farrand et al. 22 to identify samples amenable to lossof-heterozygosity analyses. However, this is the first time that the systematic quantification of amplification-competent DNA has been applied to the optimization of Taqmanbased genotyping assays.
In this report, we demonstrate that a multiplex PCR using 100-700 bp amplicons from the GAPDH gene can identify FFPE tissue-derived DNA samples that are too fragmented to genotype. As the majority of samples amenable to genotype analysis demonstrated amplification of at least the 100 bp amplicon in this multiplex analysis, the 100 bp amplicon was chosen as a marker of AQ-DNA. In addition, assessing AQ-DNA based on a minimum fragment size of 100 bp is in line with previous reports with regard to optimal amplicon size in genotype assessment and other PCR-based analyses from archival tissue. 5, 6, 15, 22, 24, 25 We show that the amount of AQ-DNA in FFPE-derived samples, relative to a highquality DNA control, can be quantified based on real-time quantitative PCR-based amplification of this amplicon (Figure 2) . Optimization of Taqman-based genotyping assays using this quantification showed that using minimal quantities of AQ-DNA (as little as 50 pg per reaction) actually improves genotyping efficiency (Figure 4) . On the basis of this optimization and quantification, sample yield increased to an average of B1250 assays (at 100 pg per assay) from a single 10 mm section ( Figure 5 ). However, it is important to note that the minimal amount of AQ-DNA required for reliable genotyping varied for each individual Taqman-based assay, ranging from 50 to 150 pg in the Taqman assays tested in this report. Importantly, as our measurements of AQ-DNA are on the basis of the use of high-quality DNA as a calibrator, individual assessment of AQ-DNA necessary per reaction will be likely be laboratory dependent, based on the calibrator used. However, the end results of increased efficiency and increased sample yield will still apply. Individual genotyping assays will also require specific optimization for ideal amplification of both the mutant and wild-type probe sets in each assay. Our optimization of the CYP2D6 1846G4A assay (Table 1) shows that although some genotypes can be assessed using as low as 10 pg of input AQ-DNA, some allele-specific Taqman reagents may not amplify efficiently until more AQ-DNA is added to the reaction. This may be most important in the case of heterozygote genotypes. As seen in Table 1 , sample J would have been assessed as a homozygous mutant if only 50 pg of DNA were used. As only one copy of the mutant gene was present per genome, additional DNA was required to achieve optimal amplification of this gene. Taqman-based assays must be optimized to allow the amplification of the mutant or wild-type allele for heterozygotes, and should ideally be performed with known controls of each potential genotype.
We also evaluated the usefulness of FFPE block tumor cores and stroma cores, which were of the type used to generate TMAs, in performing genotype analysis. We observed that tumor tissue cores yield a comparable amount of AQ-DNA to a matched section; however, matched stroma cores yielded considerably less AQ-DNA vs both sections and tumor cores ( Figure 5 ). DNA from tumor cores have slightly decreased but comparable quality vs sections as determined by multiplex PCR; however, stroma core-derived samples showed significantly decreased quality ( Table 2 , Supplementary Figure S1 ). These initial observations with DNA obtained from tumor cores suggested that such samples may serve as a useful source of DNA for SNP genotype analysis. We then evaluated real-time PCR amplification efficiency and genotyping success rates for each sample type ( Figure 7 ). To determine genotype accuracy, we compared genotypes across sample types, as we and others have reported that genotypes obtained from tissue sections were 100% concordant with matched germline samples. [2] [3] [4] 12, 13 In spite of decreased success in initial genotype assessment in both tumor and stroma cores, it was possible to determine a genotype from the majority of all sample types with repeated optimization and assessment. However, in this study we did observe a decreased concordance between section and tumor core genotypes for the six CYP2D6 SNPs (82.1%) and the UGT2B7*2 allele (92.3%). However, it is important to note that for all the UGT2B7*2 discordances, and five of the seven CYP2D6 discordances, the samples had been identified before genotyping as having very low AQ-DNA yields and thus unlikely amenable to genotyping. Further, the remaining two discordances in CYP2D6 genotype were due to a single SNP genotype. This SNP is used by our laboratory as a secondary confirmation of other SNP assays, and an inaccurate genotype from this SNP would not alter the predicted CYP2D6 phenotype of the patient as determined by CYP2D6 activity score (data not shown). 26, 27 Genotype discordance is likely because of both low AQ-DNA yields and decreased DNA quality as observed in Supplementary Figure S1 and Table 2 . Assay optimization (input AQ-DNA per assay, cycling conditions and so on) specifically for tumor core-derived samples is likely necessary and will potentially overcome these discordances. Further, although standard operating procedure for genotyping from sections has been to include repeat assays for 10-20% of samples to verify genotypes, increasing validation assays may be necessary for genotyping from tumor cores. This would likely reduce genotyping errors caused by decreased DNA quality. We have been unable to address the decrease in DNA quality, but not total AQ-DNA yield, from tumor cores vs sections. These differences potentially arise from sample processing from the original FFPE block; the shearing generated by either microtome slicing or core punching likely alters how nuclei are exposed and the efficiency of crosslinking removal. Further studies will be necessary to optimize DNA extraction specifically from tumor cores to obtain high AQ-DNA yield and high overall quality. Although tumor cores will potentially serve as a useful source of DNA with increased optimization, stroma cores appear to be unsuitable for reliable SNP genotype analysis by Taqman-based methods, which is largely due to poor quantity and quality of DNA yielded and subsequent assay failure. The unsuitability of stroma cores as a source of DNA may be unique to FFPE samples from breast tumors, as these cores likely contain a high proportion of adipose tissue and therefore have a relatively lower cellular density compared with the nearby tumor tissue. The usefulness of FFPE stroma cores as a source of genomic DNA for pharmacogenomic analyses will most likely need to be individually evaluated for specific tumor types.
As our AQ-DNA measurements were all performed on freshly extracted DNA, we were unable to evaluate changes in AQ-DNA values following long-term storage of extracted DNA. However, we have observed that when measuring AQ-DNA from a series of FFPE tissue-derived DNA that had been in storage at À20 1C for B2 years, these samples did not appear to contain lower amounts of AQ-DNA than other freshly extracted samples (data not shown). On the basis of these data, and the comparison of AQ-DNA yields from FFPE blocks of varying ages (Figure 6 ), we do not anticipate that increased storage time or sample age will have a major impact on AQ-DNA yields.
These data show that through the technical advances presented, the yield and genotyping efficiency of DNA from FFPE tissues can be improved. These advances should greatly increase the number of genotype analyses that can be performed using minimal amounts of valuable archival tissue from clinical trials, reducing tissue waste and increasing cost-effectiveness. Our observation that cores of tumor tissue are a potentially useful source of DNA for pharmacogenomic analyses may also make tissue procurement from clinical trials much easier. With the construction of TMAs becoming more widespread, pathologists now have the option of simply reserving an additional punch for DNA extraction. We expect that these advances will dramatically increase the usefulness of FFPE tissue for genotyping, and further provide an additional source of samples in TMA cores. This will allow for much simpler sample procurement, and greatly reduce the amount of tissue required for any pharmacogenomic analyses. and T-32 GM007767 from the National Institute of General Medical Sciences, Bethesda, MD, USA.
